Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | CEO - Singapore Volition | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 418,614 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 173,000 · Balance 418,614 F1: On February 26, 2026, the reporting person was awarded 173,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 10,400 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,400 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 173,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:30 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 173,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-001097 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 418,614 F1 · shares: On February 26, 2026, the reporting person was awarded 173,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000358 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,614 F1 · shares: On March 17, 2025, the reporting person was awarded 140,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 14,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 98,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 12,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-006095 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,614 F1 · shares: On August 15, 2025, the reporting person was awarded 12,507 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 6,254 units and 6,253 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:07 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 8,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-004375 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,107 F1 · shares: On June 1, 2025, the reporting person was awarded 8,327 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 2,776 units, 2,776 units, and 2,775 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 16,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001461 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,780 F1 · shares: On March 1, 2025, the reporting person was awarded 16,708 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,570 units, 5,569 units, and 5,569 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000612 · form4.xml · derivative · entry 2 Kway Jasmine · CIK 0001808135 · CEO -Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000612 · form4.xml · derivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO -Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2025-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 15,169 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007805 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO, Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,072 F1 · shares: On December 1, 2024, the reporting person was awarded 15,169 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,057 units, 5,056 units, and 5,056 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 15,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005507 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,903 F1 · shares: On September 1,2024, the reporting person was awarded 15,668 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,223 units, 5,223 units, and 5,222 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 16,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005028 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO, Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,235 F1 · shares: On Sept 28, 2023, the reporting person was awarded 67,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 16,750 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 5,583 units, 5,583 units, and 5,584 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 28,475 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 21,775 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 13,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003483 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,485 F1 · shares: On June 1, 2024, the reporting person was awarded 13,570 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,524 units, 4,523 units, and 4,523 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 28,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000412 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,915 F1 · shares: On September 28, 2023, the reporting person was awarded 67,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,475 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 9,492 units, 9,492 units, and 9,491 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 24, 2023 Filed Aug 25, 2023 15:49 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 5,000 | $1.20 | $6,000.00 |
DisclosureSEC source: 0001477932-23-006470 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 10,400 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 22,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005112 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,440 F1 · shares: On October 4, 2022, the reporting person was awarded 49,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 22,050 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 7,350 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 8,575 RSUs and 18,375 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 18,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000269 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,390 F1 · shares: On October 4, 2022, the reporting person was awarded 49,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,375 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 6,125 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 8,575 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 8,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007692 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,015 F1 · shares: On October 4, 2022, the reporting person was awarded 49,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,575 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three installments of 2,859 units, 2,858 units, and 2,858 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 32,869 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-004658 · form4.xml · derivative · entry 3 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,567 Underlying: Common Stock · 32,869 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,869 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 16,435 shares and 16,434 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 17,698 shares subject to the award previously vested and remain subject to time-based vesting. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,869 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 16,435 shares and 16,434 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 17,698 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 17,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004658 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,440 F1 · shares: On August 3, 2021, the reporting person was awarded 27,440 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,836 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 8,918 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 9,604 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 17,698 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-002174 · form4.xml · derivative · entry 3 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,698 Underlying: Common Stock · 17,698 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,698 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 8,849 shares on each of August 3, 2022 and August 3, 2023, respectively. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 50,567 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,698 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 8,849 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 9,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-002174 · form4.xml · nonDerivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,604 F1 · shares: On August 3, 2021, the reporting person was awarded 27,440 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 9,604 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 4,802 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009123 · form4.xml · derivative · entry 2 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 21:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0001477932-21-009123 · form4.xml · derivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2026-04-13 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 13, 2020, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 13, 2030 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007868 · form4.xml · derivative · entry 4 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001477932-21-007868 · form4.xml · derivative · entry 3 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2024-01-23 F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001477932-21-007868 · form4.xml · derivative · entry 2 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-01-01 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant). Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001477932-21-007868 · form4.xml · derivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2023-01-01 F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant). F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 1, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 1, 2027 (ten years from the original date of grant). Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 21:12 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001078782-20-000266 · primary_doc.xml · derivative · entry 1 Kway Jasmine · CIK 0001808135 · CEO-Singapore Volition 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2026-04-13 F1 · derivative.exercise_date: A total of 55,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.